A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: Finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride

International Journal of Clinical Practice

Volumn 66, Issue 11, 2012, Pages 1052-1055

  Kaplan, S A ^a   Chung, D E ^a   Lee, R K ^a   Scofield, S ^a   Te, A E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BREAST TENDERNESS; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NAUSEA; NOSE OBSTRUCTION; ORGAN SIZE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RETROSPECTIVE STUDY; SELF REPORT; SKIN IRRITATION; URINE FLOW RATE;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; DRUG SUBSTITUTION; EJACULATION; ERECTILE DYSFUNCTION; FINASTERIDE; GYNECOMASTIA; HUMANS; LIBIDO; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES;

EID: 84867526448     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.03010.x     Document Type: Article

References (9)

1. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS,. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Br J Urol Int 2011; 108: 388-94.
2. Clark RV, Hermann DJ, Cunningham GR, et al., Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrin Metab 2004; 89: 2179-84. (Pubitemid 38619850)
3. McConnell J.D., Bruskewitz R., Walsh P., et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63. (Pubitemid 28114643)
4. McConnell JD, Roehrborn CG, Bautista OM, et al., The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl J Med 2003; 349: 2387-98. (Pubitemid 37542987)
5. Roehrborn C. G., Boyle P., Nickel J. C., et al., Efficacy and safety of dual inhibitor of 5-alpha reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41. (Pubitemid 35292169)
6. Roehrborn CG, Siami P, Barkin J, et al., The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21.
7. Wurzel R, Ray P, Major-Walker K, et al., The effect of dutasteride on intraprostaticdihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer & Prost Dis 2007; 10: 149-54. (Pubitemid 46881666)
8. Geller J,. Effect of finasteride, a 5α -reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71: 1552-5. (Pubitemid 120032774)
9. McConnell JD, Wilson JD, George FW, et al., Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-8.